Loading…
Makes Exparel, a long-acting non-opioid local anesthetic, plus other non-opioid pain and orthopedic treatments.
Makes Exparel, a long-acting non-opioid local anesthetic, plus other non-opioid pain and orthopedic treatments.
Earns mostly from Exparel, which hospitals and surgery centres buy for each procedure rather than patients collecting it at a pharmacy, so use depends on surgeons adding it to their pain-management routine. The 2021 acquisition of Flexion brought Zilretta, a knee-injection drug.
Moat: narrow (IP / patents, process know-how). Proprietary liposomal drug-delivery technology extends anesthetic duration beyond generic bupivacaine.
Headquarters: Tampa, Florida, US · Founded: 2006 · Employees: 829
Size Pacira Biosciences (PCRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.45B, the 2016th largest of 3,117 United States companies the cockpit tracks. Shares closed at $36.43 on 6 Nov 2026.
Performance Over six months the shares gained 57.4%, against -22.7% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 5.7% over the last twelve months (peer median +10.7%); the operating margin is 3.7% (peer median -15.6%).
Valuation It trades at 11.8× forward earnings against a peer median of 27.5× (3rd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.5 points below its cost of capital (6.2% WACC).
Credit Pacira Biosciences has 1 bond outstanding ($288M).
Short interest Short interest is 10.7% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $746M | $726M | $701M | $675M | $667M |
| Revenue growth | — | +4% | +4% | +1% | — |
| Gross profit | $534M | $519M | $473M | $433M | $410M |
| EBITDA | $113M | $119M | $176M | $163M | $162M |
| Net income | $14.6M | $7.03M | -$99.6M | $42.0M | $15.9M |
| Free cash flow | $180M | $137M | $179M | $139M | $115M |
| Capital expenditure | $8.15M | $15.3M | $10.6M | $15.2M | $30.1M |
| Total debt | $412M | $418M | $639M | $586M | $763M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Pacira Biosciences PCRX | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.7B | +19% | -4% | 19% | 15.1× | 10.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PCRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.1% | -3.6% | 9th highest of 21 |
| 6-month return | +57.4% | -22.7% | highest of 21 |
| Distance from 52-week high | -0.6% | -42.6% | highest of 21 |
| Revenue growth (TTM) | +5.7% | +10.7% | 8th lowest of 19 |
| Operating margin | 3.7% | -15.6% | 8th highest of 19 |
| Forward P/E | 11.8× | 27.5× | 3rd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 14.9% | 10.6% | 4th least demanding of 7 |
| Growth delivered (Del g) | +11.1% | +5.8% | 3rd highest of 7 |
| Hurdle (Req g minus delivered) | +3.8 pp | -6.4 pp | 3rd most demanding of 7 |
| ROIC minus cost of capital | -3.5 pp | -8.1 pp | 6th highest of 18 |
| EV / EBITDA | 14.3× | 16.7× | 3rd cheapest of 6 |
| Net debt / EBITDA | 1.4× | -1.5× | 2nd most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% | +7.0% |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | n/a | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 45.8× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 71.6× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | n/a | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 9.4× | -15.4% | +3.9% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
Pacira Biosciences has 1 bond outstanding with $288M face value.